Pure Global Poised to Advance Its Innovative Products to Distribution Channels


Wallace Grafton

November 20th, 2018

Exclusive, News, Top News


Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF; FRA:1QS) is a growth-oriented life sciences cannabis company which plans to serve the market based on its research driven medical cannabis strategy. Pure recently announced that it is launching eight product lines for medical cannabis patients under the company’s PureSinse packaging label.

Innovative Medical Cannabis and Health & Wellness Products

The new PureSinse product line includes eight stock keeping units (SKUs) featuring a wide spectrum of products, formulations and infusions for the medical and health & wellness markets. The elegant, eco-friendly, and sustainable packaging speaks to the PureSinse culture of providing its clientele with exceptional product offerings and customer experience across all aspects of their company. An assortment of dried flower, cannabis oils, softgels, topicals, sublinguals, transdermals, edibles, and vape products are in the final stages of development to make them readily available to meet each patient’s individual needs once the company’s Health Canada sales license is in hand, which could happen in the next few weeks.

In further developments, the company is expecting to unveil a user-friendly eCommerce website that will enable medical cannabis patients to register with PureSinse, order medical cannabis online, and enjoy discreet delivery via registered courier in selected areas.

Health Canada Sales License

PureSinse recently completed the physical on-site inspections required by Health Canada prior to being granted a sales license to supply cannabis products to medical patients, as well legal adult markets, under the newly implemented Cannabis Act 2018. “We are confident that we have met all the safety, quality assurance, security, and record keeping requirements,” said Malay Panchal, CEO of Pure Global. “The inspection by Health Canada was one of the last steps prior to issuing a sales license, which will be a significant milestone for the company enabling sale of cannabis inventories to registered medical patients and provincial distributors, and the initiation of revenues for the company.”

About PureSinse

PureSinse, a wholly owned subsidiary of Pure Global, Inc, has demonstrated a commitment to a clinical approach that stems from the company’s pharmacy and physician roots. “The PureSinse brand is focused on patients,” according to Cheryl Pim, Director of New Product Development. “We will be tracking clinical outcomes through real-world studies to ensure our product lines are consistent, tailored, and available. Patients rely on consistency and dependability for their medical needs, and our research and data-driven approach will ensure our products and methods improve and evolve with the needs of our patients over time.”

Pure Global’s Brampton Operation

Pure’s commitment to continuous improvement and innovation is further evident in Pure Global’s recent acquisition of CO2 extraction, high-capacity robotic capsules, oil bottles, and vape pen cartridge filling equipment. The company’s Brampton campus has quickly transformed into a hub for a vertically farmed cultivation, high capacity extraction, laboratory testing, research and development, and a manufacturing center for branded and private label products for the wellness, food & beverage, natural health, and pharmaceutical markets.

In Brampton Phase 2 & Phase 3 construction of Pure’s 41,000 square foot production facility will include automated controlled growth cultivation systems that feature the company’s vertical farming methods.   This proprietary vertical farming system enables the facility to grow multiple tiers of canopy, exponentially increasing potential yield from the same square footage, without the use of pesticides or herbicides. Upon  expected completion in Q3 or Q4 of 2019, Pure’s Brampton production facility is anticipated to have a production capacity of minimum 8,000 kilograms.

Patient Focused Solutions for Improved Patient Outcomes

To support Pure’s continued focus on innovations in medical cannabis with the aim of helping patients across the globe, the company recently welcomed Dr. Sanjeev Goel to the PureSinse team as Chief Medical Officer. Dr. Goel, with a wealth of experience in the industry, has been a pioneer in medical cannabis. He led the formation of two resource centers for medical cannabis with over 3000 patients registered with licensed producers in Canada. Dr Goel is founder and CEO for an integrative medical practice using cutting-edge medical treatments for patients across Canada, the founder of a not-for-profit organization dedicated to empowering health care providers to improve patient care, as well as a healthcare software company to improve patient quality of care by developing the largest primary care patient portal in Canada.

Dr Goel will provide direction on projects supporting medical cannabis patients, primarily having to do with patient care experience and physician education. He will also act as the lead liaison with doctors and medical professionals, to provide guidance on medical cannabis and systems to ensure efficient, accurate patient care.

“I am thrilled to add Dr. Goel to our core team to help deliver patient-focused solutions enabling better education and ultimately improved patient outcomes”, said Malay Panchal. “Dr. Goel’s extensive experience as a practicing physician will allow him to offer advice regarding clinical research projects, strategies to address the needs of wellness customers, and ways to integrate existing and new wellness products.”

With these recent positive developments, Pure Global Inc appears to be a company to watch as a potential leader in the cannabis industry in Canada and worldwide.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Wallace Grafton



Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading